drug

Kuvan

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by New York State Psychiatric Institute, Washington Heights Community Service
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Kuvan in People With Schizophrenia and Schizoaffective Disorder
NCT01706965Phase 1, Phase 2Completed

KOLs & investigators

1
Jeffrey A Lieberman, M.D.KOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
New York State Psychiatric Institute, Washington Heights Community Service
company
trial
Kuvan in People With Schizophrenia and Schizoaffective Disorder
PHASE1, PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Jeffrey A Lieberman, M.D.
KOL score 5
person